HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.

Abstract
A 45-year-old male with rhinocerebral mucormycosis (Rhizopus oryzae), refractory to liposomal amphotericin B and posaconazole, received isavuconazole salvage therapy. Initial isavuconazole plasma and tissue levels were 0.76-0.86 μg/mL and 1.09-1.38 μg/g. Plasma levels increased to 1.3-3.24 μg/mL with reduced comedication. Isavuconazole was well tolerated, and the patient has remained disease-free 24 months post-antifungal therapy.
AuthorsJ Ervens, M Ghannoum, B Graf, S Schwartz
JournalInfection (Infection) Vol. 42 Issue 2 Pg. 429-32 (Apr 2014) ISSN: 1439-0973 [Electronic] Germany
PMID24217961 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antifungal Agents
  • Nitriles
  • Pyridines
  • Triazoles
  • isavuconazole
Topics
  • Antifungal Agents (therapeutic use)
  • Brain Diseases (drug therapy, microbiology, surgery)
  • Humans
  • Male
  • Middle Aged
  • Mucormycosis (drug therapy, microbiology, surgery)
  • Nitriles (therapeutic use)
  • Pyridines (therapeutic use)
  • Rhizopus (genetics, isolation & purification, physiology)
  • Salvage Therapy
  • Treatment Outcome
  • Triazoles (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: